MoonLake Immunotherapeutics
Narrative signal
MoonLake Immunotherapeutics’s revenue growth stands at 0% for Dec 2024. Year-over-year, the metric shifted by +0 pts, translating into a – rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
Valuation Signals
Track how the market prices earnings, book value, and operating cash flow for rapid context on relative multiples.
Profitability Pulse
Follow margin structure and return ratios that benchmark execution quality and capital efficiency.
Growth Momentum
Gauge the trajectory of revenue, earnings, and free cash flow expansion to understand durability.
Cash & Balance Sheet
Monitor liquidity, leverage, and free cash flow capacity that underpin resilience across cycles.
AlphaPilot quick take
• MoonLake Immunotherapeutics trades at $14.90 with a market footprint around $949.1M.
• Operating within Healthcare — Biotechnology offers instant peer context.
• Dashboard highlight: revenue growth at 0%, refreshed from the live fundamentals feed.
• Pivot into AlphaPilot deep dives to benchmark valuation, execution, and resilience.
Company profile
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics (MLTX) stock FAQs
Quick answers sourced from live Financial Modeling Prep fundamentals and AlphaPilot portfolio guidance.
What is MoonLake Immunotherapeutics (MLTX) stock price today?
MoonLake Immunotherapeutics (MLTX) trades near $14.90 as of Dec 5, 2025, 9:00 PM. Quotes refresh throughout the trading day in USD via Financial Modeling Prep, which powers the AlphaPilot dashboard.
What is MoonLake Immunotherapeutics's market capitalization?
MoonLake Immunotherapeutics's equity is valued around $949.1M, based on the latest share price multiplied by shares outstanding reported to Financial Modeling Prep.
What is the 52-week range for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics's 52-week range runs from $5.95 — $62.75. Comparing the current price to this band helps visualize positioning versus the past year's highs and lows.
How active is trading in MoonLake Immunotherapeutics stock?
MoonLake Immunotherapeutics most recently moved about 1.3M shares. Elevated volume often signals strong investor interest or fresh catalysts.
Does MoonLake Immunotherapeutics pay a dividend?
MoonLake Immunotherapeutics currently yields roughly 0%. Dividend yield divides the last 12 months of payouts by the latest share price, providing a quick income snapshot.
What is MoonLake Immunotherapeutics's intraday trading range?
MoonLake Immunotherapeutics has traded between $14.84 — $15.34 so far today. Monitoring the intraday span highlights short-term volatility relative to the longer 52-week range.
Where does the MoonLake Immunotherapeutics stock data come from?
AlphaPilot sources quotes, fundamentals, and intraday chart data for MoonLake Immunotherapeutics from the Financial Modeling Prep institutional API. The summary page blends live pricing with fundamentals that refresh after every earnings release or regulatory filing.